15 April 2026
Swissmedic: Intended Adoption of Recommendations from the EU ADRA Project
The ADRA project, which was launched in the EU, aims to adjust dosage regimens and withdrawal periods for antibiotics with older authorisations that were granted without clinical trials. Swissmedic intends to adopt the results of the project for the relevant veterinary medicinal products once concrete recommendations from the European Medicines Agency (EMA) are available.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting